Claims

1. An antibody-comprising formulation comprising
i) histidine-aspartate buffer and arginine-aspartate, or
ii) histidine-glutamate buffer and arginine-glutamate, wherein a concentration of the antibody is 100 mg/ml or more.

2. The formulation according to claim 1, which does not comprise chloride ion and acetate ion.

3. The formulation according to claim 1 or 2, which additionally comprises a sugar.

4. The formulation according to any one of claims 1 to 3, wherein the antibody is a humanized antibody or a human antibody.

5. The formulation according to any one of claims 1 to 4, wherein a concentration of the antibody is 100 to 250 mg/ml.

6. The formulation according to any one of claims 1 to 5, which is a liquid formulation.

7. The formulation according to claim 6, wherein a viscosity of the liquid formulation is 30 mPa·s or less.

8. The formulation according to claim 6 or 7, which has not been subjected to lyophilization during preparation of the formulation.

9. The formulation according to any one of claims 6 to 8, which is frozen stored at -30°C to -10°C.

10.The formulation according to any one of claims 1 to 5, wherein the formulation is a lyophilized formulation.

11. The formulation according to any one of claims 1 to 10, wherein a concentration of the buffer is 5 to 100 mM.

12. The formulation according to any one of claims 1 to 11, wherein a concentration of the arginine is 5 to 300 mM.

13. The formulation according to any one of claims 1 to 12, wherein the antibody is an anti-IL-6 receptor antibody.

14. The formulation according to any one of claims 1 to 13, wherein the buffer comprises only amino acid(s).

15. The formulation according to any one of claims 1 to 14, which is for subcutaneous administration.